{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:29:57Z","timestamp":1791350997819,"version":"4.3.1"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21272140"],"award-info":[{"award-number":["21272140"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shandong Science and Technology","award":["2015ZDJS04001"],"award-info":[{"award-number":["2015ZDJS04001"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.ejmech.2017.06.067","type":"journal-article","created":{"date-parts":[[2017,6,30]],"date-time":"2017-06-30T00:46:09Z","timestamp":1498783569000},"page":"543-551","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Structural optimization elaborates novel potent Akt inhibitors with promising anticancer activity"],"prefix":"10.1016","volume":"138","author":[{"given":"Yang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanzhen","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie J.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoguang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changying","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystle","family":"Nomie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5391-7993","authenticated-orcid":false,"given":"Guisen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2017.06.067_bib1","doi-asserted-by":"crossref","first-page":"7391","DOI":"10.1038\/sj.onc.1209100","article-title":"AKT signaling in normal and malignant cells","volume":"24","author":"Testa","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2017.06.067_bib2","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3389\/fonc.2014.00064","article-title":"Targeting PI3K\/Akt\/mTOR signaling in cancer","volume":"4","author":"Porta","year":"2014","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2017.06.067_bib3","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3109\/07853890.2014.912836","article-title":"PI3K\/AKT signaling pathway and cancer: an updated review","volume":"46","author":"Martini","year":"2014","journal-title":"Ann. Med."},{"key":"10.1016\/j.ejmech.2017.06.067_bib4","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.2174\/138955711797655380","article-title":"Developments in selective small molecule ATP-targeting the serine\/threonine kinase Akt\/PKB","volume":"11","author":"Wang","year":"2011","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.06.067_bib5","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.bmc.2013.11.022","article-title":"Design, synthesis and evaluation of novel indole derivatives as AKT inhibitors","volume":"22","author":"Yang","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.06.067_bib6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1750-9378-8-49","article-title":"Akt inhibitors: mechanism of action and implications for anticancer therapeutics","volume":"8","author":"Bhutani","year":"2013","journal-title":"Infect. agents cancer"},{"key":"10.1016\/j.ejmech.2017.06.067_bib7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.21037\/sci.2016.07.02","article-title":"Will targeting PI3K\/Akt\/mTOR signaling work in hematopoietic malignancies?","volume":"3","author":"Gao","year":"2016","journal-title":"Stem Cell Investig."},{"issue":"31","key":"10.1016\/j.ejmech.2017.06.067_bib8","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1200\/JCO.2014.59.0018","article-title":"Inhibition of the PI3K\/AKT\/mTOR pathway in solid tumors","volume":"34","author":"LoRusso","year":"2016","journal-title":"J.\u00a0Clin oncol.."},{"key":"10.1016\/j.ejmech.2017.06.067_bib9","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1158\/1535-7163.MCT-07-0120","article-title":"Targeting the AKT protein kinase for cancer chemoprevention","volume":"6","author":"Crowell","year":"2007","journal-title":"Mol. cancer Ther."},{"key":"10.1016\/j.ejmech.2017.06.067_bib10","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1200\/JCO.2015.63.5904","article-title":"Mantle cell lymphoma","volume":"34","author":"Cheah","year":"2016","journal-title":"J.\u00a0Clin oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2017.06.067_bib11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/bjh.13000","article-title":"Current regimens and novel agents for mantle cell lymphoma","volume":"167","author":"Chen","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejmech.2017.06.067_bib12","first-page":"1","article-title":"The molecular pathogenesis of mantle cell lymphoma","author":"Vogt","year":"2016","journal-title":"Leukemia Lymphoma"},{"key":"10.1016\/j.ejmech.2017.06.067_bib13","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrc2230","article-title":"Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics","volume":"7","author":"Jares","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2017.06.067_bib14","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1182\/blood-2006-04-015586","article-title":"Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma","volume":"108","author":"Rudelius","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2017.06.067_bib15","doi-asserted-by":"crossref","first-page":"869","DOI":"10.3892\/ijo.2015.3306","article-title":"Akt inhibitors in cancer treatment: the long journey from drug discovery to clinical use (Review)","volume":"48","author":"Nitulescu","year":"2016","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejmech.2017.06.067_bib16","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.1021\/jm1003842","article-title":"Design of selective, ATP-competitive inhibitors of Akt","volume":"53","author":"Freeman-Cook","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2017.06.067_bib17","doi-asserted-by":"crossref","first-page":"7037","DOI":"10.1016\/j.bmcl.2010.09.112","article-title":"Discovery of dihydrothieno- and dihydrofuropyrimidines as potent pan Akt inhibitors","volume":"20","author":"Bencsik","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2017.06.067_bib18","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/ardp.201500427","article-title":"Discovery of 4-(Piperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine derivatives as Akt inhibitors","volume":"349","author":"Liu","year":"2016","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.ejmech.2017.06.067_bib19","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1182\/blood-2008-02-137737","article-title":"AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines","volume":"113","author":"Levy","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2017.06.067_bib20","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/sj.leu.2402824","article-title":"Involvement of PI3K\/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy","volume":"17","author":"Chang","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2017.06.067_bib21","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1182\/blood-2007-11-124487","article-title":"Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis","volume":"112","author":"Stolz","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2017.06.067_bib22","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1182\/blood-2008-02-137737","article-title":"AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines","volume":"113","author":"Levy","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2017.06.067_bib23","doi-asserted-by":"crossref","first-page":"5655","DOI":"10.1038\/sj.onc.1210343","article-title":"Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition","volume":"26","author":"Han","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2017.06.067_bib24","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1158\/0008-5472.CAN-07-5783","article-title":"Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity","volume":"68","author":"Rhodes","year":"2008","journal-title":"Cancer Res."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523417305214?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523417305214?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T17:02:56Z","timestamp":1569603776000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523417305214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":24,"alternative-id":["S0223523417305214"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2017.06.067","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structural optimization elaborates novel potent Akt inhibitors with promising anticancer activity","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2017.06.067","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}